BAY 61-3606

CAT:
804-HY-76474
Size:
Inquire
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
BAY 61-3606 - image 1

BAY 61-3606

  • UNSPSC Description:

    BAY 61-3606 is an orally available, ATP-competitive, reversible and highly selective Syk inhibitor with a Ki of 7.5 nM and an IC50 of 10 nM[1]. BAY 61-3606 reduces ERK1/2 and Akt phosphorylation in neuroblastoma cell[2]. BAY 61-3606 induces a large decrease of Syk phosphorylation in K-rn cell lysates[3]. Bay 61-3606 sensitizes TRAIL-induced apoptosis by downregulating Mcl-1 in breast cancer cells[4].
  • Target Antigen:

    Apoptosis; Syk
  • Type:

    Reference compound
  • Related Pathways:

    Apoptosis;Protein Tyrosine Kinase/RTK
  • Applications:

    Cancer-Kinase/protease
  • Field of Research:

    Cancer; Inflammation/Immunology
  • Assay Protocol:

    https://www.medchemexpress.com/bay-61-3606.html
  • Purity:

    98.21
  • Solubility:

    DMSO : 5 mg/mL (ultrasonic;warming;heat to 80°C)
  • Smiles:

    O=C(C1=CC=CN=C1NC2=NC(C3=CC=C(OC)C(OC)=C3)=CC4=NC=CN24)N
  • Molecular Weight:

    390.40
  • References & Citations:

    [1]Yamamoto N, et al. The orally available spleen tyrosine kinase inhibitor 2-[7-(3,4-dimethoxyphenyl)-imidazo[1,2-c]pyrimidin-5-ylamino]nicotinamide dihydrochloride (BAY 61-3606) blocks antigen-induced airway inflammation in rodents. J Pharmacol Exp Ther. 2003 Sep;306(3):1174-81.|[2]Tümmler C, et al. SYK Inhibition Potentiates the Effect of Chemotherapeutic Drugs on Neuroblastoma Cells in Vitro. Cancers (Basel). 2019 Feb 10;11(2). pii: E202.|[3]Gioia R, et al. Quantitative phosphoproteomics revealed interplay between Syk and Lyn in the resistance to nilotinib in chronic myeloid leukemia cells. Blood. 2011 Aug 25;118(8):2211-21.|[4]Kim SY, et al. Bay 61-3606 Sensitizes TRAIL-Induced Apoptosis by Downregulating Mcl-1 in Breast Cancer Cells. PLoS One. 2015 Dec 31;10(12):e0146073.Harvard Medical School LINCS LIBRARY|Int J Mol Sci. 2021, 22(7), 3323.|Research Square Preprint. 2024 Apr 19.|Front Immunol. 2018 Feb 15;9:249.|JCI Insight. 2024 Jun 13:e174746.|Mol Cancer Ther. 2024 Jun 19.|Neuro Oncol. 2018 Apr 9;20(5):621-631.|Proc Natl Acad Sci U S A. 2022 Oct 25;119(43):e2207280119.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    No Development Reported
  • CAS Number:

    732983-37-8